Method of treating adenoid vegetations

FIELD: otolaryngology.

SUBSTANCE: endoscopy-controlled tissue of adenoid vegetation is pretreated with 0.01% miramistin solution, after which 8-10 mL of 0.1% levamisol are introduced into adenoid crypts.

EFFECT: enhanced treatment efficiency due to optimal amounts and concentrations of drugs as well as methods for administration thereof.

2 ex

 

The invention relates to medicine, namely to otorhinolaryngology.

The closest technical solution is a method for the treatment of adenoid growths involving pre-treatment of nasal mucosa vasoconstrictor drugs 0.1% solution of adrenaline or 0.05% solution of naphazoline and a 3% solution of dikaina with the subsequent introduction of adjuvant dose of 0.1-0.2 mg/kg body weight, beginning 1/2 dose intramuscularly, then 1/2 dose by injecting through the nasal passages into the fabric of adenoid vegetation (Ed. mon. The USSR №1827254, M CL AC 35/25 1990).

The disadvantage of this method is the invasiveness of the treatment because of the pain of the injection, almost blindly, as injecting through the nasal passages without endoscopic techniques difficult.

The task of the invention is to increase the effectiveness of treatment of adenoid vegetation by limiting their proliferation.

This object is achieved in that in the method for the treatment of adenoid vegetation by conducting immunotherapy new is that under the control of the endoscope pretreated fabric adenoid vegetation 0, a 1% solution of Miramistin, then in the crypt of the adenoids being 8-10 ml of 0.1% solution of levamisole treatment 8-10 days 90 days.

The drug solution Miramistin 0.01% concentric and fabric treatment, adenoid vegetation has a strong bactericidal action against gram-positive and gram-negative, aerobic and anaerobic bacteria in the form of monocultures and microbial associations, as well as fungi and viruses. In addition, Miramistin does not cause allergies and irritation to the mucous membrane of the nasal cavity and nasopharynx.

Daily exposure to the drug over a period of 8-10 days with a recurrence after 90 days, helps eliminate phlegm secretion of adenoid vegetation, fabric which becomes tight.

The introduction of drugs under control of the endoscope through the tube of the syringe allows to work directly painless fabric adenoids.

Solution Miramistin 0.01% concentration of the active against the major pathogens that are present in the nasal mucus when adenoiditis, reducing its concentration does not give the full effect of the treatment, and the increase in concentrations irritating to the mucous membranes of the nasal cavity.

Introduction 8-10 ml of levamisole 0, 1% concentration in the crypt of the adenoids - natural folds of the tonsils promotes long-term effects of medicinal substances on the adenoid tissue.

The method is as follows.

The endoscope 0°, 2.7 mm in diameter, connected to the light through the fiber and to the camera, enter the total nasal move to the nasopharynx. Parallel to the endoscope under visual control enter the tube diameter 1.5 mm, length 12 cm, worn on Luer silp is with a solution of 0.01% concentration Miramistin and under visual control handle fabric adenoid vegetation, then through a tube in the crypts of the tonsils being 8-10 ml of levamisole 0.1% concentration. Procedures carried out daily for 8-10 days 90 days 4 times a year for 2-3 years.

Example No. 1.

Patient K., 6 years old, came with complaints of nasal congestion, mucopurulent nasal discharge. From a history of recurrent conservative treatment in the clinic by place of residence, including physiotherapy, the effect of short-term treatment. When endoscopic examination was determined adenoids, 2/3 overlap clearance Joan, fabric swollen, covered with thick mucus.

Diagnosis: Adenoids 2 degrees, adenoiditis.

The endoscope 0°, 2.7 mm in diameter, connected to the light through the fiber and to the camcorder, introduced by General nasal move to the nasopharynx. Parallel to the endoscope under visual control has introduced a tube with a diameter of 1.5 mm, a length of 12 cm, attached to the syringe with a solution of 0.01% concentration Miramistin. Under visual control treated lymphoid tissue adenoid vegetation solution Miramistin 0.01% concentration in an amount of 100 ml and Then through a tube in the crypts of the tonsils introduced a solution of levamisole 0.1% concentration of 8 ml. Such procedures were performed daily for 9 days. In the nasal breathing has improved, discharge from the nose stopped. When endoscopy Eskom inspection adenoid tissue is dense, 2 tbsp. 90 days was repeated course of treatment. At survey 1 year after the last treatment adenoids in the nasopharynx 2 tbsp., dense, separated no. Nasal breathing is satisfactory.

Example No. 2.

Patient E., 7 years old, came with complaints of persistent nasal discharge, frequent colds (up to 2 times per month). From the anamnesis has been repeated homeopathic treatment, anti-inflammatory treatment in the clinic by place of residence, with a short-term effect. The frequency of colds has not decreased. The examination adenoids in the nasopharynx, 1/3 block the lumen of Joan, the tissue is swollen, covered with mucus.

Diagnosis: Adenoids 1 degree, adenoiditis.

The endoscope 0°, 2.7 mm in diameter, connected to the light through the fiber and to the camcorder, introduced by General nasal move to the nasopharynx. Parallel to the endoscope under visual control has introduced a tube with a diameter of 1.5 mm, a length of 12 cm, attached to the syringe with a solution of 0.01% concentration Miramistin. Under visual control treated lymphoid tissue adenoid vegetation solution Miramistin 0.01% concentration in an amount of 100 ml and Then through a tube in the crypts of the tonsils introduced a solution of levamisole 0.1% concentration in an amount of 10 ml After treatment for 10 days swelling of the adenoid tissue is decreased, mucus in Noop is TKE and in the nasal cavity no, adenoids 1 tbsp. 90 days was a repeat course of treatment. When viewed through 1 year - nasal breathing satisfactory, in the nose swelling and discharge no. Adenoid vegetations 1 tbsp. Frequency of colds, the child fell to 3 times per year.

In the period 2000-2005, observation and treatment were examined 260 patients with a diagnosis of Adenoids 1, 2, 3 tbsp., of which 82 people (31, 3%) were referred for surgical treatment is indicated. The remaining 178 patients were treated according to the proposed method. 5 years 12 people (6,7%) out of 178 were also operated on about this disease, while at 166 (93,3%) showed a positive clinical effect: adenoids is not increased, acute adenoiditis are rare, the condition has improved. Thus, the proposed method of treatment adenoiditis hypertrophy of adenoid vegetation 1-2 tbsp. proved to be highly effective, with proper diagnosis and accurate execution of all phases of the treatment.

1. A method for the treatment of adenoid vegetations by conducting immunotherapy, wherein under control of the endoscope pretreated fabric adenoid vegetations with 0.01%solution of Miramistin, then in the crypt of the adenoids being 8-10 ml of 0.1%solution of levamisole.

2. The method according to claim 1, characterized in that the course of treatment is carried out within 8-10 days after 90 days.



 

Same patents:

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: invention relates to a method for treatment of chronic hyperplastic laryngitis. Method involves using the immunoglobulin preparation "Immunovenin" for intravenous administration that is administrated by drop route as a single dose 25.0 ml at the rate 10-20 drops/min. Method provides reducing treatment period, diminishing complications as candidiasis and amounts of relapses based on enhancing formation of antibodies, especially of G class, and retaining high phagocytic activity of neutrophiles.

EFFECT: improved method of treatment.

1 tbl, 1 ex

FIELD: otolaryngology.

SUBSTANCE: in order to treat tonsillitis, ml of 1% solution of emoxipine is introduced into lacunas of palatine tonsils, after which the latter are exposed to helium-neon laser radiation with wavelength 0.63 μm, maximum output power 10-20 mW, light spot diameter 2-3 mm, and power flow density 35-60 W/cm2, distal end of monofiber beamguide being introduced into lacuna cavity. Single dose ranges from 3.0 to 5.5 J/cm. Radiation exposition time is 2 min per 1 lacuna and full course consists of 5-7 procedures.

EFFECT: accelerated accumulation of required concentration of emoxipine in tissues of palatine tonsils so enhancing treatment efficiency.

2 tbl

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: method involves administration in patient 1% emoxipine solution in the volume 1 ml to lateral and posterior sections of mouth-pharynx after its preliminary application anesthesia with 2% lidocaine solution by submucosa injection. The treatment course is 5-10 procedures with break for 1 day. Method provides the stable clinical effect of treatment based on rapid accumulation of the required concentration of the medicinal preparation both in pharynx mucosa and in blood. Invention can be used in treatment of chronic pharyngitis.

EFFECT: improved method of treatment.

2 tbl, 1 ex

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: method involves administration to a patient 1% solution of emoxipine in volume 5 ml in the treatment course 3-4 procedures in each other day by intralacunar route. Method provides the curative effect based on deeper penetration and rapid absorption of medicinal agent possessing with antioxidant effect by palatine tonsil surface of lacunas.

EFFECT: improved treatment method.

2 tbl, 1 ex

The invention relates to medicine, otolaryngology, and can be used for the treatment of acute stenozirutego of laryngotracheobronchitis in children
The invention relates to medicine

The invention relates to the field of medicine and for the preparation of Bresolin drops nasal 0.06% and 0.1% for the treatment of diseases of the nose and throat
The invention relates to medicine, in particular to therapy, and can be used for the treatment of angina
The invention relates to medicine, namely to otolaryngology, and for the treatment of tonsillitis and pharyngitis

The invention relates to medicine, otorhinolaryngology, and can be used to treat pharyngitis

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)-valeramide and describes compounds of the formula (I): wherein E represents phenyl or isoquinoline each of that is monosubstituted with group R1 wherein R1 represents -CN, amidino-group, halogen atom, -NH2, -CH2NH2 or compound of the formula: W represents -OCHAr', -OCHA, -NHCHAr', -NHCHA, -NHCOOCHAr', -NHCONHCHAr' or piperidine-1,2-diyl; Ar' represents unsubstituted phenyl or mono- or disubstituted phenyl, Hal, A or -CF3; A represents alkyl with 1, 2, 3, 4, 5, 6 or 7 C-atoms; X represents -CONH; Y represents Ar-diyl; T represents group -(CH2)3; Ar represents unsubstituted phenyl or mono- or disubstituted phenyl, Hal, A or -CF3; Hal represents fluorine (F), chlorine (Cl), bromine (Br) or iodine (J) atoms. These compounds are the coagulation factor Xa inhibitors. Also, invention relates to a method for synthesis of compounds of the formula (I), a medicinal agent containing these compounds and using compounds of the formula (I) for preparing a drug used in treatment of thrombosis, myocardium infarction, arteriosclerosis, inflammation, apoplexy, stenocardia, restenosis after plastic surgery in vessels, intermittent lameness, migraine, tumors, tumor diseases and/or tumor metastasis and a kit (set). Also, invention relates to intermediate compounds of the formula (I-1): wherein R1 represents -NO2 or -NH2; R represents methyl, chlorine atom or trifluoromethyl and their salts. Invention provides synthesis of novel compounds possessing valuable biological properties.

EFFECT: valuable medicinal properties of compounds.

9 cl, 1 tbl, 14 ex

FIELD: biochemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to novel using inhibitors of dipeptidyl peptidase IV (DPIV) - isoleucylthiazolidine, isoleucylcyanopyrrolidine and valylpyrrolidine and their corresponding pharmaceutically acceptable acid-additive salts used in treatment and prophylaxis of colony-forming tumor cells and/or metastasis. Enumerated compounds decreased adhesion of rat tumor pulmonary cells and resulted to decrease amount of colonies of tumor cells in them and reduced metastasis.

EFFECT: valuable medicinal anticancer properties of inhibitors.

3 cl, 6 dwg, 8 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention proposes novel derivatives of thiazole that able for effective binding and activating PPARα and/or PPARγ simultaneously and, respectively, combine antiglycemic effect caused by activation of PPARγ with anti-dyslipidemic effect caused by activation of PPARα. Also, the claim describes compounds of the formula (I): wherein substitutes from R1 to R10 as well as X and Y are determined in the description and invention claim, and their pharmaceutically acceptable salts and esters also. Also, the proposed invention describes pharmaceutical compositions possessing antagonistic activity with respect to PPARα and/or PPARγ comprising compound of the formula (I) as an active component and pharmaceutically acceptable carrier and/or additive. Except for, the invention proposes claimed compounds as therapeutically active substances for treatment and/or prophylaxis of diseases mediated by agonists of PPARα and/or PPARγ, such as diabetes mellitus, non-insulin dependent diabetes mellitus, elevated blood pressure, increased level of lipids and cholesterol, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, ovary polycystic syndrome, inflammatory or proliferative diseases.

EFFECT: valuable medicinal properties of compounds.

27 cl, 140 ex

FIELD: medicine, pharmacy, fungicides.

SUBSTANCE: invention relates to a novel pharmaceutical composition as an ointment used in treatment of fungal diseases. Proposed composition comprises 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione as active substance. Ointment comprises solid petroleum paraffin, stearic acid, vaseline oil and emulsion wax as a lipophilic base and benzoic acid as special additive. Pharmaceutical composition is prepared by fusion of solid components of a base followed by addition of 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione concentrate in vaseline oil. Invention provides preparing pharmaceutical composition possessing high chemotherapeutic effectiveness and good tolerance and low toxicity that allows its using in treatment of dermatomycosis of different localization.

EFFECT: valuable medicinal properties of pharmaceutical composition.

2 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves introducing Levamisol at a peroral dose of 50 mg twice a day during 3 days into traditional therapy after having studied patient immunity state. Rusam is concurrently intramuscularly introduced at a dose of 200 mg once a day with 4-5 days long pause. The course is 3-4 injections long.

EFFECT: selective treatment of immune system chains.

FIELD: organic chemistry.

SUBSTANCE: invention relates to new polymorphous crystalline forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)-amino]-ethoxy]-benzyl]-thiazolidine-2,4-dione maleate of formula and stereomers thereof.

EFFECT: polymorphous crystalline forms of high stability.

12 cl, 1 tbl, 13 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method involves using dipeptidyl peptidase IV (DP IV or CD 26) or DP IV-like enzyme for producing drug for treating stress or anxiety cases. Inhibitors are usable in combination with neuropeptides Y. The inhibitors are transported in physiologically compatible carriers. The inhibitors are also produced as prodrugs.

EFFECT: enhanced effectiveness of treatment.

6 cl, 11 dwg, 2 tbl

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention proposes compounds of the general formula (1): wherein X is chosen from sulfur atom and methylene group; X1 is chosen from sulfur atom and methylene group; X2 is chosen from oxygen (O), sulfur (S) atoms and methylene group; X3 means -NR5 or carbonyl group; R1 means hydrogen atom or nitrile group; R and R3 are chosen independently from hydrogen atom (H) and (C1-C6)-alkyl; R4 means R4A when X3 means -NR5 and R4B when X3 means carbonyl group; R4A is chosen from -R6R7NC(=O), -R6R7NC(=S), -R8(CH2)qC(=O), -R8(CH2)qC(=S), -R8(CH2)qSO2 and -R8(CH2)qOC(=O); R4B means -R6R7N; R5 means hydrogen atom (H); R6 and R7 are chosen independently from -R8(CH2)q, or they form in common -(CH2)2-Z1-(CH2)2- or -CHR9-X2-CH2-CHR10-; R8 is chosen from hydrogen atom (H), (C1-C4)-alkyl, cycloalkyl group condensed with benzene ring, acyl, dialkylcarbamoyl, dialkylamino-group, N-alkylpiperidyl, optionally substituted aryl, optionally substituted α-alkylbenzyl, optionally substituted aroyl, optionally substituted arylsulfonyl and optionally substituted heteroaryl representing monocyclic 5- and 6-membered ring aromatic group with one or two heteroatoms chosen from nitrogen, oxygen and sulfur atoms, and derivatives of abovementioned rings condensed with benzene; R9 and R10 are chosen independently from hydrogen atom (H), hydroxymethyl and cyanomethyl groups; Z1 is chosen from -(CH2)r-, -O-, and -N((CH2)q)R8)-; Z2 means optionally the substituted ortho-phenylene group; m = 1-3; n = 0-4; p = 2-5; q = 0-3, and r = 1 or 3. Proposed compounds are inhibitors of dipeptidyl-peptidase IV and can be used in preparing pharmaceutical compositions designated for treatment of different diseases, among them, diabetes mellitus of type 2.

EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

22 cl, 8 tbl, 453 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention describes bicyclic N-acylated imidazo-3-amines or imidazo-5-amines salts of the general formula (I): wherein R1 means tert.-butyl, 1,1,3,3-tetramethylbutyl, (C4-C8)-cycloalkyl, phenyl disubstituted with (C1-C4)-alkyl, -CH2Ra wherein Ra means the group -CO(OR') wherein R' means (C1-C8)-alkyl; R2 means hydrogen atom, the group -CORb wherein Rb means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; R3 means (C1-C8)-alkyl, (C3-C8)-cycloalkyl, phenyl, pyridyl, furfuryl or thiophenyl; A means tri-linked fragment of ring of the formula: wherein R6 and R7 mean hydrogen atom or tetra-linked fragment of ring of the following formulae: wherein R4' means hydrogen atom or benzyloxy-group; R5' means hydrogen atom; R6' means hydrogen atom, (C1-C8)-alkyl or nitro- (NO2)-group; R7' means hydrogen atom, (C1-C8)-alkyl, or R6' and R7' mean in common the following fragment of ring: -CRi=CRj-CH=CH- wherein Ri and Rj mean hydrogen atom; R5'' means hydrogen, chlorine atom or (C1-C8)-alkyl; R6'' means hydrogen atom; R7''n means hydrogen atom, amino- (NH2)-group or (C1-C8)-alkyl; R4''', R6''' and R7''' mean hydrogen atom; R8 means (C1-C8)-alkyl or (C3-C8)-cycloalkyl; X means anion of inorganic or organic acid, or their acid-additive compounds. Also, invention relates to a method for their preparing and a pharmaceutical composition based on thereof. These new compounds show affinity to opiate μ-receptor and can be used, in particular, as analgesic agents.

EFFECT: improved preparing method, valuable medicinal properties of compounds and pharmaceutical compositions.

12 cl, 2 dwg, 32 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to lyophilized composition comprising epotilone in the effective amount and mannitol or cyclodextrin. The second variant of the lyophilized composition involves epotilone and hydroxypropyl-beta-cyclodextrin. The preferable content of epotilone in the lyophilized composition is from 0.1% to 1.5%, and cyclodextrin - from 90% to 99% as measured for the total mass of solid components. Epotilone-containing lyophilized compositions can be used fro preparing an anti-tumor medicinal agent useful for parenteral administration and the lyophilized composition can be reduced preferably before administration directly. Epotilone-containing lyophilized compositions show improved indices of epotilone solubility and can retain stability for 24-36 months at temperature from 2°C to 30°C being without change of the solubility index.

EFFECT: improved and valuable properties of composition.

10 cl, 4 tbl, 14 ex

FIELD: veterinary science.

SUBSTANCE: invention proposes a preparation containing myramistin, chitosan and distilled water taken in the following ratio of components, wt.-%: myramistin : chitosan : water = (0.015-0.1):0.2:100, respectively. The preparation shows high effectiveness, strongly expressed wound-healing effect and bactericidal activity and simplicity in using. Invention can be used in treatment of animals with wounds of different etiology and anatomical localization, weeping eczema, burns and others.

EFFECT: valuable medicinal properties of preparation.

1 tbl, 3 ex

Up!